Document 0811
 DOCN  M9470811
 TI    [Future possibilities of drug therapy of acquired immunodeficiency
       syndrome]
 DT    9409
 AU    Balint GS; Szent-Gyorgyi Albert Orvostudomanyi Egyetem, Szeged.
 SO    Orv Hetil. 1994 Jun 5;135(23):1235-42. Unique Identifier : AIDSLINE
       MED/94286246
 AB    Human Immunodeficiency Virus replication offers several targets for
       inhibitory compounds, the foremost presently being the HIV reverse
       transcriptase. Since the beginning of the epidemic three nucleoside
       analogue drugs--Zidovudine, Didanosine and Zalcitabine--which act at the
       reverse transcriptase enzyme are already licensed for use in
       AIDS-therapy, and others--Stavudine, Alovudine and Lamivudine--are still
       under clinical evaluation. Although there is a very significant research
       work for newer drugs for HIV-therapy, it seems that for the next future
       Zidovudine will remain the most important drug of antiretroviral
       therapy.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/EPIDEMIOLOGY/
       TRANSMISSION  Adolescence  Adult  Antiviral Agents/*THERAPEUTIC USE
       Child  English Abstract  Female  Forecasting  Human  HIV
       Infections/*DRUG THERAPY/EPIDEMIOLOGY/TRANSMISSION  India/EPIDEMIOLOGY
       Male  Middle Age  Research  Virus Replication/DRUG EFFECTS  World Health
       Organization  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).